LICR and GlaxoSmithKline (GSK), the world's second-largest pharmaceutical company, have announced the signing of an agreement whereby GSK has licensed a substantial portfolio of tumor-specific antigens from LICR.
This licensing agreement follows a long-standing collaboration between both parties - specifically with the team led by Dr. Thierry Boon (Director, Brussels Branch). More...

Dr. Thierry Boon, Director of the Branch, has been elected as a Foreign Associate of the National Academy of Sciences USA. More...

Cancer vaccines are being investigated in early-phase clinical trials around the world, with many of those trials recruiting patients with melanoma. Although tumor regressions have been seen in 10% to 20% of patients with metastatic melanoma, the great promise of cancer vaccines - controlling tumor growth and cancer spread without serious side-effects - remains as yet unrealized. This could be set to change with the publication of a new mouse model technology from a multi-national team led by investigators at the Brussels Branch of the international Ludwig Institute for Cancer Research (LICR). More...